AKT1 and plasma cell myeloma: These results indicated that PSP could increase the osteogenic differentiation of BMSCs and had the treatment potential for patients with myeloma via the regulation of phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB)/mammalian target of rapamycin (mTOR) signal pathway (17).